About Vaxxilon

Created in 2015 by Actelion, Seeberger Science, and Max Planck Innovation to discover and develop novel synthetic vaccines to prevent infections that do not have vaccines today including C. difficile and K. pneumoniae.

C. Diff and VXN-623

C. difficile is the most common pathogen of health-care acquired infections. It is one of three “urgent” threats for anti-microbial resistance (AMR). C. difficile caused over 500,000 infections in the United States alone in 2015. It is very difficult to cure and recurrence rates are very high.

Vaxxilon is developing a semi-synthetic glycoconjugate vaccine to prevent C. difficile infections.

K. pneumoniae and VXN-319

K. pneumoniae is a notorious pathogen that is responsible for respiratory and urinary tract infections that are very difficult to treat. Several strains are resistant to many types of antibiotics and have high mortality rates. It is an “urgent” AMR threat.

Synthetic Vaccines

Vaxxilon creates and develops synthetic carbohydrate vaccines. These vaccines are comprised of oligosaccharides (synthesized small fragments of naturally occurring carbohydrates) combined with a carrier protein or small molecule immune stimulator

Basel Area
Vaxxilon AG
Christoph Merian-Ring 11,
4153 Reinach, Switzerland
Berlin Area (Adlershof)
Vaxxilon Deutschland GmbH
Magnusstraße 11,
12489 Berlin, Germany

Copyright 2019 © Vaxxilon AG